Patents by Inventor Congxin Liang

Congxin Liang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11053224
    Abstract: The invention discloses polymorphic forms of a compound of formula I, pharmaceutical compositions containing same, preparation method therefor and use thereof. The compound of formula I of the present invention is as shown in formula I, of which the crystalline form can be crystalline form 1, crystalline form 2, crystalline form 3, crystalline form 5, crystalline form 6 or crystalline form 7. All the crystalline forms of the compound of formula I in the present invention have good crystalline stability and chemical stability and a decrease in purity of their main ingredient less than 2%. The preparation method of the present invention may be used to produce the various crystalline forms of the compound of formula I with high purity, and suitable for large scale production.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: July 6, 2021
    Assignee: EQUINOX SCIENCES, LLC
    Inventors: Congxin Liang, Lihua Xie
  • Patent number: 10899744
    Abstract: Provided are a compound as represented by structural formula (I) ({5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-6-aminopyridazin-3-yl}-N-{4-[((3S,5R)-3,5-di methylpiperazinyl)carbonyl]phenyl}carboxamide hydrochloride) and a novel crystalline form of a hydrate or solvate of the compound. Further provided are a manufacturing method of the compound and crystalline form, a related intermediate, a pharmaceutical composition comprising the compound, an application using the compound or the crystalline form for preparing a pharmaceutical product for treating a disease, symptom, or disorder, and a therapeutic method for treating a disease, symptom, or disorder.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: January 26, 2021
    Assignee: XCOVERY HOLDINGS, INC.
    Inventors: Congxin Liang, Yongbin Ma, Wei He
  • Patent number: 10851084
    Abstract: The new piperazine derivatives are modulators of TRPML and are useful in treating disorders related to TRPML activities such as lysosome storage diseases, muscular dystrophy, age-related common neurodegenerative diseases, oxidative stress or reactive oxygen species (ROS) related diseases, and ageing.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: December 1, 2020
    Assignee: Lysoway Therapeutics, Inc.
    Inventor: Congxin Liang
  • Publication number: 20200352921
    Abstract: The new arylsulfonamide and arylsulfone derivatives are modulators of TRPML and are useful in treating disorders related to TRPML activities and lysosome functions such as acid-related disorders and cancer.
    Type: Application
    Filed: May 6, 2018
    Publication date: November 12, 2020
    Inventor: Congxin Liang
  • Patent number: 10738060
    Abstract: The new 1H-furo[3,2-b]imidazo[4,5-d]pyridine derivatives are selective Jak1 kinase inhibitors useful in treating disorders related to Jak1 activities such as autoimmune diseases or disorders, inflammatory diseases or disorders, and cancer or neoplastic diseases or disorders.
    Type: Grant
    Filed: September 30, 2017
    Date of Patent: August 11, 2020
    Assignee: TLL Pharmaceutical, LLC
    Inventor: Congxin Liang
  • Publication number: 20190256523
    Abstract: The new 1H-furo[3,2-b]imidazo[4,5-d]pyridine derivatives are selective Jak1 kinase inhibitors useful in treating disorders related to Jak1 activities such as autoimmune diseases or disorders, inflammatory diseases or disorders, and cancer or neoplastic diseases or disorders.
    Type: Application
    Filed: September 30, 2017
    Publication date: August 22, 2019
    Inventor: Congxin Liang
  • Publication number: 20190248764
    Abstract: The new piperazine derivatives are modulators of TRPML and are useful in treating disorders related to TRPML activities such as lysosome storage diseases, muscular dystrophy, age-related common neurodegenerative diseases, oxidative stress or reactive oxygen species (ROS) related diseases, and ageing.
    Type: Application
    Filed: June 29, 2017
    Publication date: August 15, 2019
    Applicant: CalyGene Biotechnolgy, Inc.
    Inventor: Congxin Liang
  • Publication number: 20190233403
    Abstract: The invention discloses polymorphic forms of a compound of formula I, pharmaceutical compositions containing same, preparation method therefor and use thereof. The compound of formula I of the present invention is as shown in formula I, of which the crystalline form can be crystalline form 1, crystalline form 2, crystalline form 3, crystalline form 5, crystalline form 6 or crystalline form 7. All the crystalline forms of the compound of formula I in the present invention have good crystalline stability and chemical stability and a decrease in purity of their main ingredient less than 2%. The preparation method of the present invention may be used to produce the various crystalline forms of the compound of formula I with high purity, and suitable for large scale production.
    Type: Application
    Filed: September 29, 2017
    Publication date: August 1, 2019
    Inventors: Congxin LIANG, Lihua XIE
  • Publication number: 20190135792
    Abstract: Provided are a compound as represented by structural formula (I) ({5 -[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-6-aminopyridazin-3-yl}-N-{4-[((3S,5R)-3,5-di methylpiperazinyl)carbonyl]phenyl}carboxamide hydrochloride) and a novel crystalline form of a hydrate or solvate of the compound. Further provided are a manufacturing method of the compound and crystalline form, a related intermediate, a pharmaceutical composition comprising the compound, an application using the compound or the crystalline form for preparing a pharmaceutical product for treating a disease, symptom, or disorder, and a therapeutic method for treating a disease, symptom, or disorder.
    Type: Application
    Filed: June 1, 2017
    Publication date: May 9, 2019
    Inventors: Congxin LIANG, Yongbin MA, Wei HE
  • Publication number: 20180016240
    Abstract: The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against ALK and are useful in treating disorders related to abnormal protein kinase activities such as cancer, neurological and psychiatric diseases.
    Type: Application
    Filed: May 3, 2017
    Publication date: January 18, 2018
    Inventor: Congxin Liang
  • Patent number: 9580439
    Abstract: The invention provides inhibitors of focal adhesion kinase, an enzyme involved in the attachment of the cytoskeleton of a cell to an extracellular matrix, which has been implicated in processes such as cell migration, cell proliferation, and cell survival. The inhibitors are derivatives of a 5-substituted 2,4-diaminopyridine wherein the substituents are as defined herein. The invention also provides a method of using the inhibitors in treatment of cancer, and methods of preparation of the inhibitors by use of coupling reactions.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: February 28, 2017
    Assignee: The Scripps Research Institute
    Inventors: Congxin Liang, Marcel Koenig, Yuanjun He, Par Holmberg
  • Publication number: 20160176900
    Abstract: Pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
    Type: Application
    Filed: February 29, 2016
    Publication date: June 23, 2016
    Inventors: Congxin Liang, Zhigang Li
  • Patent number: 9296724
    Abstract: Pyridazine derivatives (e.g., Formula I) have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: March 29, 2016
    Assignee: Xcovery Holding Company LLC
    Inventors: Congxin Liang, Zhigang Li
  • Publication number: 20160068493
    Abstract: The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against ALK and are useful in treating disorders related to abnormal protein kinase activities such as cancer, neurological and psychiatric diseases.
    Type: Application
    Filed: September 4, 2015
    Publication date: March 10, 2016
    Inventor: Congxin Liang
  • Patent number: 9242958
    Abstract: The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against c-Met and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: January 26, 2016
    Assignee: Xcovery Holding Company LLC
    Inventor: Congxin Liang
  • Patent number: 9126947
    Abstract: The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against ALK and are useful in treating disorders related to abnormal protein kinase activities such as cancer, neurological and psychiatric diseases.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: September 8, 2015
    Assignee: Xcovery Holding Company LLC
    Inventor: Congxin Liang
  • Patent number: 8912178
    Abstract: The 4-urea-phenyl substituted 6-morpholin-4-yl-pyrazolo[3,4-d]pyrimidine derivatives are potent and selective inhibitors of mTOR kinase and are useful in treating disorders related to abnormal mTOR activities such as cancer, immune disorders, cardiovascular disease, ocular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: December 16, 2014
    Assignee: Xcovery Holdings Company, LLC
    Inventor: Congxin Liang
  • Publication number: 20140221376
    Abstract: Pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
    Type: Application
    Filed: April 9, 2014
    Publication date: August 7, 2014
    Applicant: Xcovery Holding Company, LLC
    Inventors: Congxin Liang, Zhigang Li
  • Patent number: 8697866
    Abstract: Pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: April 15, 2014
    Assignee: Xcovery Holding Company LLC
    Inventors: Congxin Liang, Zhigang Li
  • Publication number: 20140051699
    Abstract: Novel PI3K, especially PI3K delta isoform, selective inhibitors are disclosed. The compounds are useful in treating disorders related to abnormal PI3K or PI3K? activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.
    Type: Application
    Filed: October 28, 2013
    Publication date: February 20, 2014
    Applicant: Xcovery Holding Company, LLC
    Inventor: Congxin Liang